

Gaetano Facchini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5951162/gaetano-facchini-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

3,516
citations

31
h-index

51
g-index

210
ext. papers

4,273
ext. citations

3.9
avg. IF

4.88
L-index

#	Paper	IF	Citations
176	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	5
175	Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.. <i>Frontiers in Medicine</i> , 2022 , 9, 874213	4.9	0
174	Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling.. <i>Biomedicines</i> , 2021 , 9,	4.8	1
173	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046	2.5	
172	Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2021 , 17, 807-815	3.6	
171	Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study. <i>Infectious Agents and Cancer</i> , 2021 , 16, 22	3.5	4
170	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. <i>Cancers</i> , 2021 , 13,	6.6	1
169	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without Ra. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021 , 36, 391-396	3.9	
168	Acute Toxicity in Hypofractionated/Stereotactic Prostate Radiotherapy of Elderly Patients: Use of the Image-guided Radio Therapy (IGRT) Clarity System. <i>In Vivo</i> , 2021 , 35, 1849-1856	2.3	3
167	A Root in Synapsis and the Other One in the Gut Microbiome-Brain Axis: Are the Two Poles of Ketogenic Diet Enough to Challenge Glioblastoma?. <i>Frontiers in Nutrition</i> , 2021 , 8, 703392	6.2	1
166	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021 , 155, 56-63	7.5	3
165	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021 , 17, 3291-3299	3.6	5
164	Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e286-e298	3.3	6
163	Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study. <i>Frontiers in Oncology</i> , 2020 , 10, 594	5.3	12
162	Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2633-2638	8.8	3
161	Resveratrol in Cancer Patients: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	32
160	Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. <i>European Review for Medical and Pharmacological Sciences</i> , 2020 , 24, 4040-4047	2.9	208

159	Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17593-e17593	2.2	
158	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020 , 15, 495-501	5	12
157	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABlitude study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968725	5.4	3
156	Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. <i>Antioxidants</i> , 2020 , 9,	7.1	14
155	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1513-1525	21.7	13
154	The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department. <i>Future Science OA</i> , 2020 , 7, FSO635	2.7	2
153	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019 , 17, 296	8.5	7
152	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 291-298	3.3	18
151	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497	5.7	17
150	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019 , 15, 1115-1123	3.6	5
149	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 529.e1-529.e7	2.8	4
148	Extragenital germ cell tumors: Not just a matter of location. A review about clinical, molecular and pathological features. <i>Cancer Medicine</i> , 2019 , 8, 6832-6840	4.8	37
147	Prognostic and predictive factors in testicular cancer. <i>European Review for Medical and Pharmacological Sciences</i> , 2019 , 23, 3885-3891	2.9	5
146	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS345-TPS345	2.2	
145	PAZopanib as first line in METastatic RCC patients: A Real-world Italian experience (PAMERIT study) Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 611-611	2.2	
144	Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience. <i>Anti-Cancer Drugs</i> , 2019 , 30, 179-185	2.4	8
143	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 42-45	2.7	12
142	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1400	5.3	21

141	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019 , 74, 35-42	14.4	20
140	Proanthocyanidins and the risk of prostate cancer in Italy. <i>Cancer Causes and Control</i> , 2018 , 29, 261-268	2.8	8
139	Ipilimumab for the treatment of metastatic prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 205-213	5.4	8
138	Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 194-206	21.7	86
137	Processed Meat and Risk of Renal Cell and Bladder Cancers. <i>Nutrition and Cancer</i> , 2018 , 70, 418-424	2.8	6
136	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15
135	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17
134	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951	3.3	22
133	The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. <i>Current Cancer Drug Targets</i> , 2018 , 18, 430-441	2.8	1
132	Melanoma Adjuvant Treatment: Current Insight and Clinical Features. <i>Current Cancer Drug Targets</i> , 2018 , 18, 442-456	2.8	3
131	Optimal Management of Prostate Cancer Based on its Natural Clinical History. <i>Current Cancer Drug Targets</i> , 2018 , 18, 457-467	2.8	6
130	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 705-709	2.4	1
129	Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 322-322	2.2	1
128	Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS405-TPS405 ²	2.2	1
127	Exploring the molecular aspects associated with testicular germ cell tumors: a review. <i>Oncotarget</i> , 2018 , 9, 1365-1379	3.3	16
126	Coffee consumption is not associated with ovarian cancer risk: a dose-response meta-analysis of prospective cohort studies. <i>Oncotarget</i> , 2018 , 9, 20807-20815	3.3	12
125	Current and Emerging Treatments for Metastatic Renal Cell Carcinoma. <i>Current Cancer Drug Targets</i> , 2018 , 18, 468-479	2.8	16
124	Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review. <i>European Review for Medical and Pharmacological Sciences</i> , 2018 , 22, 645-661	2.9	11

123	Primitive Mediastinal Germ Cell Tumors: An Update. <i>Current Clinical Pathology</i> , 2018 , 215-227	0.1	
122	Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS396-TPS396	2.2	
121	Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment. <i>Neuroradiology Journal</i> , 2018 , 31, 18-26	2	15
120	Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. <i>Journal of Global Oncology</i> , 2018 , 4, 1-12	2.6	4
119	Microbiota effects on cancer: from risks to therapies. <i>Oncotarget</i> , 2018 , 9, 17915-17927	3.3	101
118	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22
117	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018 , 14, 2691-2699	3.6	2
116	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 355-359.e1	3.3	22
115	First-Line Pazopanib in Non-clear-cell Renal Carcinoma: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e609-e614	3.3	30
114	Serum and tissue markers in colorectal cancer: State of art. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 111, 103-116	7	19
113	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017 , 77, 1012-1019	4.2	4
112	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
111	Family history of cancer and the risk of bladder cancer: A case-control study from Italy. <i>Cancer Epidemiology</i> , 2017 , 48, 29-35	2.8	14
110	Associations of dietary carbohydrates, glycaemic index and glycaemic load with risk of bladder cancer: a case-control study. <i>British Journal of Nutrition</i> , 2017 , 118, 722-729	3.6	9
109	ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review. <i>International Journal of Medical Sciences</i> , 2017 , 14, 554-559	3.7	2
108	A rare case of malignant solitary fibrous tumor in prostate with review of the literature. <i>Diagnostic Pathology</i> , 2017 , 12, 50	3	21
107	Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis. <i>Oncotarget</i> , 2017 , 8, 17383-17395	3.3	15
106	Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey. <i>Oncotarget</i> , 2017 , 8, 24401-24414	3.3	66

105	Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results. <i>Anti-Cancer Drugs</i> , 2017 , 28, 104-109	2.4	15
104	Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. <i>Gynecologic Oncology</i> , 2017 , 144, 72-76	4.9	21
103	Epithelial-mesenchymal transition in prostate cancer: an overview. <i>Oncotarget</i> , 2017 , 8, 35376-35389	3.3	105
102	Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences. <i>Oncotarget</i> , 2017 , 8, 30606-30616	3.3	32
101	Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 2017 , 8, 484	5.6	3
100	Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results. <i>Frontiers in Pharmacology</i> , 2017 , 8, 797	5.6	4
99	Micrnas in prostate cancer: an overview. <i>Oncotarget</i> , 2017 , 8, 50240-50251	3.3	76
98	Coffee Decreases the Risk of Endometrial Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies. <i>Nutrients</i> , 2017 , 9,	6.7	25
97	Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. <i>Oncotarget</i> , 2017 , 8, 14192-14220	3.3	45
96	Testicular cancer from diagnosis to epigenetic factors. <i>Oncotarget</i> , 2017 , 8, 104654-104663	3.3	36
95	Epigenetic Changes Induced by Green Tea Catechins are Associated with Prostate Cancer. <i>Current Molecular Medicine</i> , 2017 , 17, 405-420	2.5	21
94	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16503-e16503	2.2	
93	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16521-e16521	2.2	
92	Activity of second line axitinib in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib: Results from SAX Italian real world trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16054-e16054 ^{2.2}		
91	New treatment strategies for HIV-positive cancer patients undergoing antineoplastic chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2391-2403	4	3
90	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. <i>Cancer Biology and Therapy</i> , 2016 , 17, 1213-1220	4.6	38
89	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
88	Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer. <i>Oncology</i> , 2016 , 90, 29-35	3.6	12

87	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. <i>Oncotarget</i> , 2016 , 7, 85641-85649	3.3	18
86	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 40085-40094	3.3	13
85	Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review). <i>Oncology Reports</i> , 2016 , 36, 603-12	3.5	27
84	Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 210-210	2.2	
83	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 325-325	2.2	
82	Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 326-326	2.2	
81	Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor to predict overall survival.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 219-219	2.2	
80	Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2016 , 7, 428	5.6	48
79	Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. <i>BioMed Research International</i> , 2016 , 2016, 9750795	3	37
78	From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. <i>Frontiers in Pharmacology</i> , 2016 , 7, 110	5.6	4
77	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. <i>Frontiers in Pharmacology</i> , 2016 , 7, 123	5.6	26
76	Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". <i>Frontiers in Pharmacology</i> , 2016 , 7, 287	5.6	8
75	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 331	5.6	12
74	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016 , 7, 376	5.6	93
73	Tumour biomarkers: homeostasis as a novel prognostic indicator. <i>Open Biology</i> , 2016 , 6,	7	18
72	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
71	Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015 , 11, 965-73	3.6	9
70	The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows. <i>Anti-Cancer Drugs</i> , 2015 , 26, 123-38	2.4	15

69	Gene interference strategies as a new tool for the treatment of prostate cancer. <i>Endocrine</i> , 2015 , 49, 588-605	4	23
68	Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study. <i>Future Oncology</i> , 2015 , 11, 219-24	3.6	7
67	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
66	Ovarian cancer standard of care: are there real alternatives?. <i>Chinese Journal of Cancer</i> , 2015 , 34, 17-27		58
65	Endocrine disruptors and female cancer: Informing the patients (Review). <i>Oncology Reports</i> , 2015 , 34, 3-11	3.5	19
64	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62
63	Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9). <i>Oncology</i> , 2014 , 86, 351-8	3.6	11
62	Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk. <i>Anti-Cancer Drugs</i> , 2014 , 25, 745-50	2.4	7
61	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 48	12.8	23
60	Long-Term Response to Pazopanib in an Elderly Man with mRCC. A Case Report. <i>Tumori</i> , 2014 , 100, e305-e308	1.7	2
59	Long-term response to pazopanib in an elderly man with mRCC. A case report. <i>Tumori</i> , 2014 , 100, e305-8	1.7	2
58	Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1567-74	5.6	11
57	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
56	Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. <i>Journal of Drug Delivery</i> , 2013 , 2013, 898146	2.3	38
55	Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. <i>Anti-Cancer Drugs</i> , 2013 , 24, 1069-78	2.4	25
54	Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?. <i>Anti-Cancer Drugs</i> , 2013 , 24, 989-98	2.4	16
53	Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 212-8	2.4	28
52	Testicular and testicular adnexa tumors in the elderly. <i>Anti-Cancer Drugs</i> , 2013 , 24, 228-36	2.4	8

51	Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression. <i>Current Medicinal Chemistry</i> , 2013 , 20, 833-839	4.3	29
50	Multidisciplinary treatment of early stage endometrial cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013 , 13, 861-71	2.2	3
49	Neuroendocrine Differentiation in Prostate Cancer 2013 , 87-109		
48	Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 90-90	2.2	
47	Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 208-208	2.2	
46	Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 191-6	4.8	31
45	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. <i>Oncology Reports</i> , 2012 , 27, 409-15	3.5	13
44	High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. <i>Current Cancer Drug Targets</i> , 2012 , 12, 693-702	2.8	25
43	Chemotherapy in epithelial ovarian cancer. <i>Cancer Letters</i> , 2011 , 303, 73-83	9.9	70
42	Expression of lumbosacral HOX genes, crucial in kidney organogenesis, is systematically deregulated in clear cell kidney cancers. <i>Anti-Cancer Drugs</i> , 2011 , 22, 392-401	2.4	8
41	Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. <i>Clinical Journal of Pain</i> , 2011 , 27, 9-18	3.5	71
40	Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. <i>Annals of Oncology</i> , 2011 , 22 Suppl 8, viii40-viii44	10.3	25
39	The role of tissue microarray in the era of target-based agents. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 859-69	3.5	21
38	Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. <i>Cancer Biology and Therapy</i> , 2010 , 10, 543-8	4.6	43
37	Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. <i>Current Cancer Drug Targets</i> , 2010 , 10, 772-81	2.8	65
36	First-line treatment of advanced ovarian cancer: current research and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 47-60	3.5	67
35	Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 209-18	3.5	20
34	Treatment of recurrent epithelial ovarian cancer. <i>Therapeutics and Clinical Risk Management</i> , 2009 , 5, 421-6	2.9	23

33	Target-based agents in neoadjuvant treatment of liver metastases from colorectal cancer: secret weapons in anti-cancer war?. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1709-18	4.6	2
32	Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. <i>British Journal of Cancer</i> , 2009 , 100, 1566-74	8.7	125
31	New treatment approaches in renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2009 , 20, 893-900	2.4	33
30	Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group. <i>Clinical Journal of Pain</i> , 2009 , 25, 671-82	3.5	7
29	Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. <i>Current Cancer Drug Targets</i> , 2009 , 9, 690-704	2.8	40
28	Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 79-85	1.6	7
27	Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan. <i>Annals of Oncology</i> , 2007 , 18, 1579-80	10.3	1
26	Phase II studies of anticancer chemotherapy: indirect evidence of poor quality. <i>Annals of Oncology</i> , 2007 , 18, 403	10.3	1
25	Concomitant occurrence of facial cutaneous and parotid gland metastases from rectal cancer after preoperative chemoradiotherapy. <i>Oncology Research and Treatment</i> , 2007 , 30, 324-6	2.8	3
24	The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). <i>Journal of Experimental and Clinical Cancer Research</i> , 2007 , 26, 307-12		10
23	Overexpression of both CXCL chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. <i>Clinical Cancer Research</i> , 2006 , 12, 2795-803	12.9	148
22	Stop Flow in abdominal and pelvic cancer relapses. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 1284-8	2.8	4
21	Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 2566-75	2.8	19
20	Gastric cancer. Treatment of advanced disease and new drugs. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 3122-6	2.8	6
19	A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications. <i>Annals of Oncology</i> , 2005 , 16, 1980-1	10.3	2
18	Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 663-70	3.6	18
17	Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. <i>Thyroid</i> , 2002 , 12, 815-21	6.2	100
16	Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer. <i>Lung Cancer</i> , 2000 , 30, 203-10	5.9	10

15	Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 921-6	2.2	65
14	Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998 , 47, 91-7	4.4	23
13	Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1997 , 41, 86-90	3.5	8
12	Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer. <i>European Journal of Cancer</i> , 1996 , 32A, 1901-4	7.5	7
11	Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1995 , 35, 243-8	4.4	6
10	Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas. <i>Leukemia and Lymphoma</i> , 1995 , 17, 147-53	1.9	2
9	A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. <i>British Journal of Cancer</i> , 1995 , 72, 1256-8	8.7	19
8	A phase-ii trial of 5-Fluorouracil, folinic Acid, vinorelbine in pretreated patients with metastatic colorectal-cancer. <i>Oncology Reports</i> , 1995 , 2, 513-6	3.5	2
7	Neoadjuvant chemotherapy in locally advanced gastric-cancer - preliminary-results of a phase-ii trial with a modified famtx combination. <i>Oncology Reports</i> , 1995 , 2, 727-30	3.5	6
6	Preoperative chemoimmunotherapy with Carboplatin, epidoxorubicin, 5-Fluorouracil and alpha-2b interferon in locally advanced inoperable gastric-cancer. <i>International Journal of Oncology</i> , 1994 , 4, 1271 ¹ -5		
5	Hyperfractionated split-course thoracic radiation-therapy plus chemotherapy in locally advanced nonsmall cell lung-cancer. <i>International Journal of Oncology</i> , 1994 , 4, 577-82	1	
4	Recovery of sensitivity to cisplatin and epidoxorubicin by ionidamine and interferon in advanced ovarian-cancer. <i>International Journal of Oncology</i> , 1994 , 4, 1265-9	1	
3	Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study. <i>European Journal of Cancer</i> , 1994 , 30A, 946-50	7.5	6
2	Immunological and Clinical Effects of Thymostimulin in Patients with Locally Advanced Non-Small-Cell Lung Cancer Treated with Combined Chemoradiotherapy. <i>Drug Investigation</i> , 1994 , 7, 209-214		3
1	Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease. <i>Gynecologic Oncology</i> , 1993 , 50, 60-7	4.9	11